奥精医疗(688613.SH)公告，公司于2024年8月向国家药监局递交了公司可吸收复合骨修复材料医疗器械 产品的注册申报资料。公司于近日收到国家药监局通知，公司可吸收复合骨修复材料医疗器械产品获得 批准。 ...

智通财经APP讯，奥精医疗(688613.SH)公告，公司于2024年8月向国家药监局递交了公司可吸收复合骨 修复材料医疗器械产品的注册申报资料。公司于近日收到国家药监局通知，公司可吸收复合骨修复材料 医疗器械产品获得批准。 ...

人民财讯9月28日电，奥精医疗(688613)9月28日公告，公司近日收到国家药监局通知，公司可吸收复合 骨修复材料医疗器械产品获得批准。 此次获得可吸收复合骨修复材料医疗器械产品是在现有产品技术的基础上，引入可吸收聚酯材料，在具 有前代产品优良的生物相容性及促进骨愈合能力的前提下，进一步增加了材料强度，并增强了材料降解 可控性，能够更好地满足临床中不同条件下的骨缺损修复。 ...

本次获得可吸收复合骨修复材料医疗器械产品是在现有产品技术（人工骨修复材料，注册证号： 20193131531）的基础上，引入可吸收聚酯材料，在具有前代产品优良的生物相容性及促进骨愈合能力 的前提下，进一步增加了材料强度，并增强了材料降解可控性，能够更好的满足临床中不同条件下的骨 缺损修复。奥精医疗拥有可吸收复合骨修复材料医疗器械产品的完全自主知识产权，产品关键技术是骨 修复材料领域的重大进展，是生物材料领域的原始创新，开辟了一条自主制备生物材料的新途径，达到 国际领先水平。 格隆汇9月28日丨奥精医疗(688613.SH)公布，公司于2024年8月向国家药监局递交了公司可吸收复合骨 修复材料医疗器械产品的注册申报资料。公司于近日收到国家药监局通知，公司可吸收复合骨修复材料 医疗器械产品获得批准。 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-054 奥精医疗科技股份有限公司 自愿披露关于公司产品获得注册证的公告 本次公司产品获得注册证，进一步完善了公司在骨修复材料领域产品的布局， 拓宽了公司销售的产品种类，有利于公司国内市场的整体拓展。 上述产品的实际销售业绩取决于产品的实际竞争力和市场销售能力，目前尚无 法预测对公司未来经营业绩的影响，敬请广大投资者谨慎投资，注意投资风险。 特此公告。 奥精医疗科技股份有限公司董事会 奥精医疗科技股份有限公司（以下简称"公司"）于2024年8月向国家药监局递 交了公司可吸收复合骨修复材料医疗器械产品的注册申报资料。公司于近日收到国 家药监局通知，公司可吸收复合骨修复材料医疗器械产品获得批准。现将相关情况 公告如下： 一、注册证内容 注册证编号：国械注准20253131942 产品名称：可吸收复合骨修复材料 证件有效期：2025.09.25-2030.09.24 产品分类：三类 二、医疗器械基本情况 本次获得可吸收复合骨修复材料医疗器械产品是在现有产品技术（人工骨修复 材料，注册证号：20193131531）的基础上，引入可吸收聚酯材料，在具有前代产 ...

Core Viewpoint - The company, AoJing Medical, has received approval from the National Medical Products Administration for its absorbable composite bone repair material medical device, marking a significant advancement in the field of biomaterials [1] Group 1: Product Development - The company submitted the registration application for the absorbable composite bone repair material medical device in August 2024 [1] - The new product builds on existing technology (artificial bone repair material, registration number: 20193131531) by incorporating absorbable polyester materials [1] - The new material enhances strength and controllable degradation while maintaining excellent biocompatibility and bone healing promotion capabilities [1] Group 2: Intellectual Property and Innovation - AoJing Medical holds complete independent intellectual property rights for the absorbable composite bone repair material medical device [1] - The key technology of this product represents a major breakthrough in the field of bone repair materials and is considered original innovation in biomaterials [1] - This development opens a new pathway for the independent preparation of biomaterials, achieving an internationally leading level [1]

奥精医疗(688613.SH)公告称，公司于2024年8月向国家药监局递交了可吸收复合骨修复材料的注册申报 资料，并于近日收到国家药监局通知，该产品获得批准。该产品是在现有产品技术的基础上，引入可吸 收聚酯材料，增强了材料强度和降解可控性，能更好地满足临床中不同条件下的骨缺损修复。该产品为 公司自主研发，拥有完全自主知识产权，技术达到国际领先水平。该产品获得注册证，进一步完善了公 司在骨修复材料领域的产品布局，有利于公司国内市场的整体拓展，但实际销售业绩取决于产品竞争力 和市场销售能力，目前无法预测对公司未来经营业绩的影响。 ...

Group 1 - The core point of the news is that BioVeda China RMB Investment Limited has reduced its shareholding in Aojing Medical Technology Co., Ltd., bringing its stake below 5% [18][19][23] - The shareholding before the reduction was 7,239,358 shares, accounting for 5.28% of the total shares [8] - After the reduction, BioVeda holds 6,850,430 shares, which is 5% of the total shares [9][10] Group 2 - The reduction was executed through block trading and centralized bidding on the Shanghai Stock Exchange [7][10] - The total number of shares reduced was 388,928, representing 0.28% of the total shares [20] - BioVeda has stated that it may continue to reduce its holdings in the next 12 months, adhering to relevant legal disclosure obligations [6][23] Group 3 - The reduction does not trigger a mandatory tender offer and will not change the controlling shareholder or actual controller of Aojing Medical [18][23] - BioVeda has confirmed that there are no restrictions on the rights of the shares held, such as pledges or freezes [11] - The company has complied with all relevant laws and regulations regarding the share reduction [20][33]

Core Viewpoint - The announcement details a share reduction plan by major shareholder Beijing Qilun Tianyou Venture Capital Co., Ltd. for Aojing Medical Technology Co., Ltd., indicating a planned reduction of up to 1,355,515 shares, which represents 1% of the total shares outstanding [3][6]. Group 1: Major Shareholder Information - As of the announcement date, Qilun Tianyou holds 8,468,000 shares, accounting for 6.18% of Aojing Medical's total shares [2]. - The shares held by Qilun Tianyou were acquired prior to the company's initial public offering and have been tradable since May 23, 2022 [2]. Group 2: Share Reduction Plan Details - Qilun Tianyou plans to reduce its holdings through centralized bidding and block trading, with a maximum reduction of 1,355,515 shares [3]. - The reduction will occur within three months following a 15-day period after the announcement, specifically from October 23, 2025, to January 23, 2026 [3]. Group 3: Compliance and Commitments - Qilun Tianyou has previously committed to not transferring or entrusting the management of its shares for twelve months following the company's stock listing [5]. - The current reduction plan is consistent with prior commitments made by the major shareholder [6]. Group 4: Other Shareholder Activities - BioVeda China RMB Investment Limited has also reduced its holdings, decreasing its stake to 5% after selling 388,928 shares, which is 0.28% of the total shares [12][13]. - The reduction by BioVeda does not trigger a change in control of the company and complies with relevant regulations [12][16].

Core Viewpoint - Qilin Tianyou plans to reduce its stake in AoJing Medical by up to 1% of the total shares, which amounts to a maximum of 1.3555 million shares, due to its own financial arrangements [1] Company Summary - AoJing Medical (688613.SH) has received a notice from Qilin Tianyou regarding its share reduction plan [1] - The reduction will be executed through centralized bidding and block trading methods [1] Stakeholder Actions - Qilin Tianyou intends to sell shares based on market conditions [1]